Fig. 5

T6I-29–1 A inhibits tumor growth in preliminary in vivo studies. Female NOD/SCID mice were orthotopically injected with ESR1 MCF7 Y537S cells bilaterally in mammary fat pad #4. Mice received silastic E2 implant surgery 1 week before cell injection. A) Tumor growth (error bars indicate SEM) in I.P. pilot study, n = 4–8 tumors/ group. Two-way Anova measures significance with Bonferroni post-hoc test; results indicate day 9 treatment analysis. B) Total metastatic lesions as measured by H&E staining by Dr. Khin Su Mon across groups. C) Survival curve of I.P. pilot study, significance determined using log-rank test. Veh vs. 100 mg/kg p = 0.0624. D) Representative photos capturing metastases (top to bottom) in the liver (vehicle-treated), left femur (vehicle-treated), adrenal gland (100 mg/kg treated), and uterus (vehicle-treated). E) Tumor growth (error bars indicate SEM) in oral pilot study, n = 6 tumors/ group. Analyzed with Two-Way Anova with Bonferroni post-hoc test. F) Tumor luminescence of oral pilot study measured weekly (error bars indicate SEM). Analyzed with unpaired t-test at treatment week 3. G) Luminescence of the liver, lung, brain, femurs, and uterus were measured for each mouse in each group ex vivo (error bars indicate s.d.), and results were graphed based on treatment groups, including both sides of organ luminescent signal. Anova with Tukey post-hoc statistical test was used to determine significance